Pfizer Inc. (PFE)
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates. Innovent will will co-commercialize with Pfizer in the U.S. and Europe and share profits but retain rights in the Greater China market.
Insiders Aren't Buying Pfizer Stock at $26 and That's Actually a Good Thing
The smart money on Pfizer (NYSE: PFE | PFE Price Prediction) is sending a quieter signal than the financial press typically rewards: institutional analysts are constructive, insiders are not transacting in size in either direction, and the dividend yield is doing the heavy lifting.
Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?
PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy
PFE's aggressive M&A and in-house R&D efforts are paying off, with the growth portfolio (newly launched/acquired products) already delivering $3.1B in revenues in FQ1'26 (+22% YoY operationally). LOE risks are mitigated by delayed Vyndamax generic entry to mid-2031, supporting the management's high single-digit 5Y revenue growth guidance from 2029 onwards. PFE's intermediate-term performance is expected to remain lumpy, but the cost saving efforts, strong interest coverage, and dividend sustainability underpin its compelling investment thesis.
FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer
Johnson & Johnson offers a superior return/risk profile versus Pfizer, driven by consistency and operational stability. PFE's far lower valuation (FWD P/E 8.55x, PEGY 0.97x) and far higher yield (6.79%) are certainly attractive. But JNJ's 63-year streak of dividend growth, lower payout ratio (48.46%), ongoing buybacks, and stable inventory all point to far superior consistency.
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion
PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.
Why Pfizer Stock Still Looks Deeply Undervalued In 2026
Marty Makary resigned from his position as FDA Commissioner on May 12, in my view, in part because of his inconsistent policy approach. The FDA leadership shake-up continues to this day, but as I'll explain below, this period of uncertainty isn't creating pressure on Big Pharma players, including Pfizer. By the way, Pfizer is still my favorite in the oncology drugs market, trading at a non-GAAP P/E ratio of 8.6x and a high 6.8% dividend yield.
Let's Talk About Your Big “But”
The 1985 classic Pee Wee's Big Adventure is one of my favorite movies. In it, there's a scene where Pee Wee and Simone sit inside the Cabazon dinosaurs as she talks about her dream of going to Paris.
PFE Stock Declines Post Q1 Beat: Book Profits or Stay Invested?
Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.
Pfizer's Turnaround Is Taking Shape
Pfizer generated $14.5 billion in Q1 revenue, rising 5.7% YoY and beating estimates by $649 million. Acquired products delivered $3.1 billion in Q1 revenue with 22% operational growth, supporting Pfizer's patent cliff transition strategy. Vyndamax exclusivity extension into FY31 reduces Pfizer's projected revenue exposure from $17 billion to approximately $14-$15 billion.
